REGENERON PHARMACEUTICALS (REGN)
US75886F1075 - Common Stock
We assign a fundamental rating of 6 out of 10 to REGN. REGN was compared to 586 industry peers in the Biotechnology industry. REGN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. REGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year REGN was profitable.
In the past year REGN had a positive cash flow from operations.
Each year in the past 5 years REGN has been profitable.
REGN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of REGN (11.22%) is better than 97.78% of its industry peers.
REGN's Return On Equity of 14.29% is amongst the best of the industry. REGN outperforms 96.75% of its industry peers.
REGN's Return On Invested Capital of 10.23% is amongst the best of the industry. REGN outperforms 96.24% of its industry peers.
REGN had an Average Return On Invested Capital over the past 3 years of 19.76%. This is above the industry average of 14.94%.
The last Return On Invested Capital (10.23%) for REGN is well below the 3 year average (19.76%), which needs to be investigated, but indicates that REGN had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.22% | ||
| ROE | 14.29% | ||
| ROIC | 10.24% |
ROA(3y)19.52%
ROA(5y)18.66%
ROE(3y)25.8%
ROE(5y)25.67%
ROIC(3y)19.76%
ROIC(5y)18.51%
1.3 Margins
REGN has a Profit Margin of 29.45%. This is amongst the best in the industry. REGN outperforms 98.46% of its industry peers.
REGN's Profit Margin has declined in the last couple of years.
REGN's Operating Margin of 30.45% is amongst the best of the industry. REGN outperforms 98.46% of its industry peers.
In the last couple of years the Operating Margin of REGN has declined.
REGN's Gross Margin of 86.32% is amongst the best of the industry. REGN outperforms 90.60% of its industry peers.
In the last couple of years the Gross Margin of REGN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.45% | ||
| PM (TTM) | 29.45% | ||
| GM | 86.32% |
OM growth 3Y-8.48%
OM growth 5Y-3.09%
PM growth 3Y-10%
PM growth 5Y-3.71%
GM growth 3Y-0.25%
GM growth 5Y-1.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so REGN is creating value.
REGN has less shares outstanding than it did 1 year ago.
REGN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, REGN has an improved debt to assets ratio.
2.2 Solvency
REGN has an Altman-Z score of 11.24. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
REGN has a Altman-Z score of 11.24. This is amongst the best in the industry. REGN outperforms 86.84% of its industry peers.
REGN has a debt to FCF ratio of 0.69. This is a very positive value and a sign of high solvency as it would only need 0.69 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.69, REGN belongs to the top of the industry, outperforming 96.75% of the companies in the same industry.
A Debt/Equity ratio of 0.10 indicates that REGN is not too dependend on debt financing.
REGN has a Debt to Equity ratio of 0.10. This is in the lower half of the industry: REGN underperforms 63.59% of its industry peers.
Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.69 | ||
| Altman-Z | 11.24 |
ROIC/WACC1.16
WACC8.85%
2.3 Liquidity
A Current Ratio of 5.27 indicates that REGN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.27, REGN is in line with its industry, outperforming 54.36% of the companies in the same industry.
REGN has a Quick Ratio of 4.51. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
REGN has a Quick ratio (4.51) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.27 | ||
| Quick Ratio | 4.51 |
3. Growth
3.1 Past
REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.73%.
The Earnings Per Share has been growing by 13.91% on average over the past years. This is quite good.
Looking at the last year, REGN shows a small growth in Revenue. The Revenue has grown by 5.90% in the last year.
The Revenue has been growing by 14.34% on average over the past years. This is quite good.
EPS 1Y (TTM)-0.73%
EPS 3Y11.42%
EPS 5Y13.91%
EPS growth Q2Q-5.35%
Revenue 1Y (TTM)5.9%
Revenue growth 3Y15.57%
Revenue growth 5Y14.34%
Revenue growth Q2Q-0.54%
3.2 Future
REGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.50% yearly.
Based on estimates for the next years, REGN will show a small growth in Revenue. The Revenue will grow by 7.13% on average per year.
EPS Next Y4.51%
EPS Next 2Y5.04%
EPS Next 3Y6.39%
EPS Next 5Y8.5%
Revenue Next Year7.74%
Revenue Next 2Y7.62%
Revenue Next 3Y7.25%
Revenue Next 5Y7.13%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 22.72, the valuation of REGN can be described as rather expensive.
96.24% of the companies in the same industry are more expensive than REGN, based on the Price/Earnings ratio.
REGN is valuated rather cheaply when we compare the Price/Earnings ratio to 28.60, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 20.34 indicates a rather expensive valuation of REGN.
Based on the Price/Forward Earnings ratio, REGN is valued cheaply inside the industry as 94.87% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of REGN to the average of the S&P500 Index (20.15), we can say REGN is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.72 | ||
| Fwd PE | 20.34 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.56% of the companies listed in the same industry.
REGN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. REGN is cheaper than 97.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.54 | ||
| EV/EBITDA | 20.91 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates REGN does not grow enough to justify the current Price/Earnings ratio.
REGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)5.04
PEG (5Y)1.63
EPS Next 2Y5.04%
EPS Next 3Y6.39%
5. Dividend
5.1 Amount
REGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REGENERON PHARMACEUTICALS
NASDAQ:REGN (5/17/2024, 7:23:07 PM)
After market: 982.29 0 (0%)982.29
+14.31 (+1.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap108.24B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.72 | ||
| Fwd PE | 20.34 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)5.04
PEG (5Y)1.63
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.22% | ||
| ROE | 14.29% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 30.45% | ||
| PM (TTM) | 29.45% | ||
| GM | 86.32% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.27 | ||
| Quick Ratio | 4.51 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-0.73%
EPS 3Y11.42%
EPS 5Y
EPS growth Q2Q
EPS Next Y4.51%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)5.9%
Revenue growth 3Y15.57%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y